Crescendo Biologics
Crescendo Biologics is focused on developing novel immune cell enhancing therapeutics in immuno-oncology. Their platform, Humabody® VH, enables rapid discovery of fully human VH domains with superior tissue penetration and diverse delivery routes. The company collaborates globally with leading institutions and partners with major biotech firms, backed by prominent investors, to advance their pipeline and technology.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Small-format bispecific immune cell engager (PSMA-targeted)
A small-format bispecific immune-cell engager directed at PSMA-expressing solid tumours; advanced into Phase 1/1b clinical development.
Topical single-domain VH therapeutic for inflammatory skin disease
A topical formulation of a VH-based therapeutic developed for psoriasis that has progressed into partner-led clinical trials (partner initiated Phase 2).
PD-1 x LAG-3 multispecific VH therapeutic (preclinical / published)
A multispecific VH-based therapeutic targeting PD-1 and LAG-3 with preclinical data published and presented as part of development activities.
Preclinical multispecific '2-in-1' immune cell engager
A preclinical multispecific immune cell engager designed to combine two functional activities in a single small-format molecule.
VH-based CAR-T construct technology (preclinical)
Preclinical technology demonstrating the use of VH binders to generate monospecific and bispecific CAR-T cells targeting solid tumours.
Small-format bispecific immune cell engager (PSMA-targeted)
A small-format bispecific immune-cell engager directed at PSMA-expressing solid tumours; advanced into Phase 1/1b clinical development.
Topical single-domain VH therapeutic for inflammatory skin disease
A topical formulation of a VH-based therapeutic developed for psoriasis that has progressed into partner-led clinical trials (partner initiated Phase 2).
PD-1 x LAG-3 multispecific VH therapeutic (preclinical / published)
A multispecific VH-based therapeutic targeting PD-1 and LAG-3 with preclinical data published and presented as part of development activities.
Preclinical multispecific '2-in-1' immune cell engager
A preclinical multispecific immune cell engager designed to combine two functional activities in a single small-format molecule.
VH-based CAR-T construct technology (preclinical)
Preclinical technology demonstrating the use of VH binders to generate monospecific and bispecific CAR-T cells targeting solid tumours.
Services
Identification and engineering of fully human single-domain VH binding domains against oncology and immunology targets for internal and partnered programs.
Design and assembly of multispecific VH-based therapeutics with tuneable half-life and multi-route delivery options.
Support for preclinical in vivo studies, biodistribution and tumour penetration assays, and clinical trial execution for early-phase oncology programs.
Development of expression and manufacturing processes for small-format biologics and engagement with CDMOs for clinical supply.
Out-licensing of candidate programs and multi-target discovery collaborations with pharmaceutical partners and academic groups.
Identification and engineering of fully human single-domain VH binding domains against oncology and immunology targets for internal and partnered programs.
Design and assembly of multispecific VH-based therapeutics with tuneable half-life and multi-route delivery options.
Support for preclinical in vivo studies, biodistribution and tumour penetration assays, and clinical trial execution for early-phase oncology programs.
Development of expression and manufacturing processes for small-format biologics and engagement with CDMOs for clinical supply.
Out-licensing of candidate programs and multi-target discovery collaborations with pharmaceutical partners and academic groups.
Expertise Areas
- Immuno-oncology therapeutics
- Single-domain antibody (VH) discovery and engineering
- Multispecific biologics design
- Preclinical in vivo evaluation (tumour penetration, biodistribution)
Key Technologies
- Single-domain antibody (VH) platform
- Transgenic mouse models for antibody generation
- Multispecific protein engineering
- Flexible linker assembly for multispecific formats